GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Valuation Rank

IPHA (Innate Pharma) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Innate Pharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Valuation Rank
Comparable Companies
XPAR:ADOC XPAR:IVA XPAR:MAAT XPAR:TNG XPAR:NANO XPAR:ALCLS XPAR:ALSEN XPAR:OSE XPAR:DBV XPAR:GNFT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IPHYF:USA 0EVI:UK IPH:France IDDA:Germany IDD:Germany IDD:Germany
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.